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ABSTRACT
Objectives: A qualitative study of the BREATHER
(PENTA 16) randomised clinical trial, which compared
virological control of Short Cycle Therapy (SCT)
(5 days on: 2 days off ) with continuous efavirenz
(EFV)-based antiretroviral therapy (CT) in children and
young people (aged 8–24) living with HIV with viral
load <50 c/mL to examine adaptation, acceptability and
experience of SCT to inform intervention development.
Setting: Paediatric HIV clinics in the UK (2), Ireland
(1), the USA (1) and Uganda (1).
Participants: All BREATHER trial participants who
were over the age of 10 and aware of their HIV
diagnosis were invited to participate. 49 young people
from both arms of the BREATHER trial (31 females and
18 males; 40% of the total trial population in the
respective sites; age range 11–24) gave additional
consent to participate in the qualitative study.
Results: Young people from both trial arms had initial
concerns about the impact of SCT on their health and
adherence, but these decreased over the early months
in the trial. Young people randomised to SCT reported
preference for SCT compared with CT pre-trial.
Attitudes to SCT did not vary greatly by gender or
country. Once short-term adaptation challenges were
overcome, SCT was positively described as reducing
impact of side effects, easing the pressure to carry and
remember medication and enabling more weekend
social activities. Young people on both arms reported
frequent medication side effects and occasional missed
doses that they had rarely voiced to clinical staff.
Participants liked SCT by trial end but were concerned
that peers who had most problems adhering could find
SCT disruptive and difficult to manage.
Conclusions: To realise the potential of SCT (and
mitigate possible risks of longer interruptions), careful
dissemination and communication post-trial is needed.
SCT should be provided alongside a package of
monitoring, support and education over 3 months to
allow adaptation.
Trial registration number: NCT 01641016
INTRODUCTION
Rates of antiretroviral therapy (ART) adher-
ence tend to be lower among young people
(aged 10–24) living with HIV compared with
their adult counterparts in all settings,
despite important geographical variations.1–3
Multiple social aspects of adherence for the
paediatric HIV population need to be taken
into consideration alongside the speciﬁc con-
texts of local HIV epidemics.4 Lack of disclos-
ure of their HIV status and, commonly,
insufﬁcient discussions about the implica-
tions of HIV and ART often fail to adequately
support young people’s ongoing adherence.5
Limited control over their living environ-
ments and secrecy surrounding HIV and
treatment-taking represent signiﬁcant bar-
riers to adherence.6–9 Treatment fatigue in
facing a lifetime of ART is considered an
important reason for poor adherence among
young people living with HIV as with other
long-term conditions,10–12 although little
Strengths and limitations of this study
▪ Including a qualitative study in the trial has
enriched our understanding of the impact and
influence of Short Cycle Therapy (SCT) on
young people’s experiences of adherence.
Understanding their perspectives and experiences
is crucial for the intervention to be effective
beyond the trial.
▪ By specifically acknowledging adherence chal-
lenges in childhood and adolescence, if framed
thoughtfully, healthcare staff can use SCT to
show a greater contextual understanding about
the reasons why and ways in which treatment
can get disrupted.
▪ A key limitation of our study is the narrow popu-
lation on which these findings are based (relying
on those agreeing to participate in the clinical
trial and then also in the qualitative study).
▪ Being in the trial may in and of itself have been
conducive to better adherence, due to the
increased support and monitoring in the study,
particularly in contexts with little or no routine
access to this level of care.
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HIV research investigates this from the perspectives of
young people themselves.
We report on the ﬁndings from a qualitative study
undertaken as part of BREATHER (PENTA 16).
BREATHER is a global, phase II, randomised, multicen-
tre, non-inferiority trial testing the efﬁcacy of Short
Cycle Therapy (SCT) (5 days on /2 days off) for young
people living with HIV (aged 8–24) on an efavirenz
(EFV)-based combination.13 Among the inclusion cri-
teria for the BREATHER trial were: having an undetect-
able viral load and being on an EFV-based combination
for the prior 12 months. Treatment interruption inter-
ventions, including SCT, aim to encourage long-term
adherence by offering patients regulated time off medi-
cation. The trial design to test having the weekends off
treatment was informed by anecdotal evidence suggest-
ing that managed interruptions can ameliorate the chal-
lenges of adhering continuously.14
The qualitative study aimed to explore the experiences
of SCT, and of treatment and care more generally,
among a sample of trial participants (aged 10–24). SCT
is a behavioural intervention relying on self-administered
ART and self-reported adherence. We used qualitative
methods to elucidate whether SCT was an acceptable
intervention to the target patient group and to inform
any potential SCT roll-out, to ensure it is clinically efﬁca-
cious and effective for the people involved.15
METHODOLOGY
The qualitative study employed a longitudinal, mixed-
methods design and took place in the UK, Ireland, the
USA and Uganda. All young people recruited into the
BREATHER trial in these countries, and aged 10–24,
were eligible to participate in our study. This was subject
to self-awareness of HIV infection (for at least 6
months), since not all trial participants were aware of
their HIV-positive status. Children under the age of 10
were not deemed old enough to participate meaning-
fully in our qualitative research. In addition to consent
procedures for the clinical trial, we carried out separate
consent and assent procedures as appropriate and parti-
cipants were reimbursed at rates in line with standard
local research practices.
A longitudinal design was adopted. The ﬁrst interview,
conducted (in all three sites) towards the start of the trial
explored participants’ attitudes towards taking HIV treat-
ment and whether or not this ﬁt in with their daily lives
and priorities. The second interview, conducted (in all
three sites) at least 9 months into the trial, focused on
their experience of being in the trial, including their atti-
tudes towards SCT. The third interview, conducted (only
in Uganda and UK) towards the end of the trial, investi-
gated their ongoing experience of the trial and their pre-
ferences for future treatment options. We also conducted
focus group discussions (FGDs) in Uganda after the trial
ﬁndings had been explained to participants by clinicians
in this site. The data were collected by SB, SN and two
other Ugandan researchers, none of whom were known
to the participants prior to the study. Interviews and
FGDs lasted between 45 and 120 min and were con-
ducted with participants in the clinic, apart from an
interview conducted in one participant’s home at their
request. Audio-recorded data were transcribed verbatim
and translated into English where appropriate. Personal
identifying details have been removed.
The topic guide for each phase included uniform key
area of investigation but not a list of prescribed ques-
tions. Though the overarching focus was similar, the
guides were ﬂexible enough to ensure interviewers
could adapt the form and nature of the questions to the
circumstances and maturity of the individual participant.
Data analysis was conducted by all members of the
research team. A grounded analytic approach to qualita-
tive thematic analysis was adopted, using systematic case
comparison.16 17 A discussion was held after each inter-
view to consider emerging analytical ideas and oppor-
tunities to reﬁne the interview guide and approach. The
coding was done inductively and individually developed.
These preliminary codes were then exchanged among
the team, discussed and reconciled into an agreed
coding framework, which was subsequently applied to
the data. We then conducted an iterative comparison of
codes extracted from the multiple interview data for
each research participant. These are corroborated with
the use of ‘negative case’ analysis, built by including
instances in the data that differ or counteract emerging
ﬁndings and explanations.
SAMPLE
Repeat interviews were conducted with 43 young people.
The qualitative sample in each site reﬂects the diversity
of the trial population in terms of sex, age and ethnicity.
A total of 26 young people were recruited in Uganda
from 1 clinic (Kampala), 7 in the UK and Ireland from
3 clinics (hospitals in London, Nottingham and Dublin)
and 10 in the USA from 1 clinic (Memphis). We report
combined data on the small samples in UK and Ireland
to avoid participant identiﬁcation.
The only difference that we noted by site was in study
recruitment and engagement. In the USA, we recruited
all participants who were eligible and enrolled in the
trial at the time of the phase one ﬁeldwork (numerical
saturation) and in Uganda we recruited participants
until we reached theoretical saturation. There were
greater challenges to recruitment in the UK, for the trial
and the qualitative study. While we were unable to
collect data on this, our impression is of potential
research fatigue given the extent of clinical trial research
conducted among this relatively small clinical popula-
tion. Nonetheless, overall recruitment response and
retention through the repeated phases of the qualitative
study was high, and the qualitative study sample also
represented a signiﬁcant proportion of the sample for
the BREATHER trial in all countries (43/199 trial parti-
cipants overall) (see tables 1 and 2).
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We conducted four FGDs in Uganda after the trial
ﬁndings had been reported to the study participants by
clinicians. At this point, trial participants had moved
into a follow-up phase of the trial and were continuing
in their same assigned treatment arms. In addition to
including a theoretically informed subsample of the
interview sample, we invited six further trial participants,
who had not previously been involved in the qualitative
study, to take part in the FGDs to broaden our under-
standing of the acceptability of SCT across the trial
patient group.
In this article, we have chosen to use only randomised
arm and country of origin as identiﬁers for the quotes.
This is to protect the anonymity and conﬁdentiality of
the small sample.
FINDINGS
We report on the experiences of participants from both
arms (rather than just those on SCT) to address the ques-
tion of acceptability of the intervention to the patient
target group. Given that they were randomly assigned to
the intervention or control arm, they all had equal
chance of being put onto SCT. Hence, all participants
had important insights to share about how they perceived
SCT as an intervention for young people living with HIV.
It is critical to note that we did not ﬁnd signiﬁcant differ-
ences in experience or attitudes to SCT by gender, age or
country site. The slight differences we noted were limited
to the style of accounting across countries and ages, but
there was no variation by content.
Overall participants described a positive SCT experi-
ence and a preference for SCT over continuous therapy
(CT). However, those in the SCT arm described chal-
lenges adapting to SCT in the short term. Young people
from both arms discussed having initial anxieties about
the impact SCT could have on their health and
adherence patterns, but these concerns decreased after
the ﬁrst few months in the trial.
Early concerns about SCT
In the early stages of the trial, young people from both
arms discussed anxieties about the possible impact of
SCT on their health and adherence patterns:
I thought that it [SCT] would be harmful … Because I
was taking a break yet I was not used to that. (Uganda,
SCT arm)
Some worried they might mistake or forget the days
on and the days off. They were concerned that any mis-
takes would damage their health, and that they could
not predict changes in their own behaviour or in their
bodies:
[The thought] was bothering me just a little bit to take
off two days…I might miss an extra day, because then I
might be scared that something might go on and my
body might change a certain way. (USA, CT arm)
Adaptation to SCT
Concerns decreased over the ﬁrst few months in the
trial when participants on SCT did not observe any
explicit adverse effects. However, almost all the partici-
pants on the SCT arm reported challenges in initially
adapting to the new routine:
Oh, that was hectic…when I ﬁrst started the study, I
think the ﬁrst week I think I took it on a day that I wasn’t
supposed to take it because I’m so used to it. But now
I’m used to it. (USA, SCT arm)
Many found it difﬁcult to deliberately miss treatment,
when they had consistently been encouraged to take
their pills every day:
Table 2 Focus Group Discussions sample overview
FGD
Age range at
point of FGD Mean age No of participants Male Female SCT CT
FGD 1 13–15 13.5 6 4 2 4 2
FGD 2 15–17 15.7 7 2 5 5 2
FGD 3 19–24 21 7 4 3 2 5
FGD 4 16–20 18 5 2 3 2 3
CT, continuous therapy; FGD, focus group discussions; SCT, short cycle therapy.
Table 1 In-depth interview sample overview
Country No. Male Female On SCT On CT
Switched or
left trial
Age range
at phase 1
Mean
age
Response
rate
Uganda 26 12 14 14 10 2 (to CT) 11–22 16 26/66
UK (and Ireland) 7 5 2 4 3 – 12–17 15 7/23
USA 10 9 1 4 5 1 (from trial) 18–22 20 10/14
Total 43 26 17 22 18 3 11–22 17 43/103
CT, continuous therapy; SCT, short cycle therapy.
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Because being so used to taking it seven days a week and
then now they’re saying I can take two days off, it’s like a
slight change and if you don’t get your mind focused…
basically it’s like when you’re so used to something and
then you’re trying to change it, it takes time. (USA, SCT
arm)
SCT also temporarily affected some of the participants’
autonomy in treatment taking. To adapt to their new
treatment schedule, some had to reverse the independ-
ence gained by managing their own treatment, and tem-
porarily ask for supervision from their carers after
having been in sole charge of their adherence for some
time. The adaptation period was relatively short, and
young people tended to become used to the new
routine within 2–10 weeks.
Only one participant reported being unable to adapt
to the changes brought by SCT and at their request was
returned to CT.
It is me who even told the Doctor that I want to go out
of this short cycle. Because I used to miss. If I miss I
would miss even Monday. (Uganda, Changed back from
SCT to CT arm)
All the others on SCT reported getting used to their
new regimen and even ﬁnding that having 2 days off
helped them to adhere to their medication for the
remaining 5 days of the week. SCT thus worked as a
reminder and as a reward:
It [SCT] gives you the courage to take your drugs daily
other than in the other days. Reason being that you will
say that I have missed to take the drugs in these two days
that means that in the remaining days I have to be vigi-
lant to take the drugs such that I can have the guts to
rest in these other days [two days]. (Uganda, SCT arm)
Many reported ﬁnding it ‘liberating’ to not have to
remember, carry and take treatment at the weekends.
This enabled them to socialise more, without worrying
about ﬁnding a private space to take pills:
I don’t know what it is about those two days, but it’s the
best days ever (…) I can go somewhere and not have to
worry about taking that pill. Sometimes when I take the
pill, my stomach hurts sometimes (…) but I don’t have
to worry about that, and I don’t have to worry about
taking this big pill, and I don’t got to worry about
coming home at a certain time and taking it, I don’t got
to worry about getting up and taking it. I’m just free for
those two days. (USA, SCT arm)
It gave me freedom inside my heart and I saw that eeh at
least here I have started to be like a normal person.
(Uganda, SCT arm)
It is important to note that the challenges in adapting
to SCT only came up in the later waves of data collec-
tion, although many participants would have been going
through these around the time of their ﬁrst interview.
They may have found it easier to identify a problem
retrospectively once it had been addressed, but their
conﬁdence in what they could tell us in interviews also
increased. Indeed, some also mentioned in later inter-
views that they did not voice their ambivalence or pro-
blems with SCT at the start of the trial for fear that they
would be moved to the CT arm.
Missing doses and ART side effects
SCT brought respite also because some participants felt
that there was a ‘legitimate’ way to miss doses. They were
reassured by the trial that their medication had contin-
ued to be effective even if they had not been adhering
100% to their regimen:
If you don’t have a break you may forget to take drugs
like on a Saturday or Sunday but if you are supposed to
have a break it is acceptable. (Uganda, SCT arm)
SCT thus eased the pressure to never miss any treat-
ment. Knowing they could have the weekends off, and
worrying about missing cumulative doses, many were
instead motivated to take their treatment diligently for
the remainder of the week:
I’d probably have been a bit more cautious…you’re
already missing two days so…you kind of get the impres-
sion you can’t really miss another one. (UK, SCT arm)
Nonetheless, although described by those working in
the clinics as ‘exemplary adherers’ with undetectable
viral loads, participants did report missing doses occa-
sionally and intermittently—when on CT or outside of
the prescribed SCT days. Participants interpreted stable
viral load results as justiﬁcation to avoid reporting ‘slip-
pages’ to their clinicians:
I try not to hide anything, it’s just that I probably feel like
a smidge ashamed … because I’d have told them if they
asked, but if they didn’t ask then and I ﬁnd out my viral
load was undetectable then I just let out a sigh of relief
and keep going. (USA, SCT arm)
Similarly, young people from both randomised arms
reported frequent and sometimes disabling treatment
side effects that had so far been difﬁcult to voice in the
clinic:
I used to take it while at school but I would feel dizzy.
After taking it at 9:30pm I could not read by 10pm and
would not be able to walk properly yet I didn’t want to
disturb other children so I would just lie down there.
(Uganda, SCT arm)
Some participants discussed having to change the
time of the day when they took their medicines, and
adapt day-to-day activities to cope with side effects:
The doses at 5 … when I was in school I tried switching
it to me taking it in the morning…it wasn’t really such a
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good idea but that feeling of being high at school was
not the best situation, I don’t like that at all because I
mean I can’t concentrate, [I] feel like I’m not really
there. (USA, CT arm)
Participants also reported that side effects were not
felt on the days when they did not take their medication,
so SCT afforded them a welcome break. In this way,
some participants reported that SCT made the experi-
ence of taking treatment more bearable:
I don’t get hot ﬂushes on the weekends and I can stay up
a little bit longer…It’s like your body starts getting woozy
and weak and now on the weekends it’s like, I’m just still
full of energy. So it’s better, much better. (USA, SCT
arm)
Holding back ‘truths’ in the clinic
Encouragingly, most participants greatly valued their
relationship with clinicians and appreciated the care
and support that they received. However, this could
translate into feeling under pressure to be the ‘ideal
patient’ for their clinicians, which inhibited candid dis-
cussions about adherence problems.
The label of ‘exemplary adherers’ applied in the
clinic to trial participants (based on their undetectable
viral load) demonstrates inherent challenges within the
clinical relationship: it is difﬁcult to be informed about
young people’s adherence behaviour if they are so
anxious about the consequences of being ‘found out’.
Further, limited disclosure of non-adherence affected
young people’s capacity to receive tailored adherence
support. Participants said it was easier to tell the
researchers in our study about their missed doses
because they were not connected to the clinic and did
not fear that they would ‘quarrel or abuse’ them.
Keeping the secret
We found that young people often miss doses when they
are in social situations that present a risk of being seen
taking their treatment. Hence participants emphasised
that the many beneﬁts of SCT stemmed from reducing
the visibility of ART in social situations. This is illustrative
of young people’s broader concerns, which underpin
non-adherence at certain times:
It becomes tiresome to take the drugs every day because
there are times when you are away from home or
amongst people who don’t know about you…So whoever
sees you becomes eager to know what you are taking or
what you are hiding. In my opinion having to rest is good
because sometimes you may be amongst people like on a
Saturday or Sunday but you are not going to take drugs
so no one will get to know about your health. (Uganda,
SCT arm)
SCT as ‘progress’ and reward
SCT, and the BREATHER trial more generally, also sym-
bolised scientiﬁc progress to young people, a step
towards a foreseeable future of better HIV therapy, when
they might be able to take even less medication or a
cure for HIV may be found. This may be particularly
valuable for those initiated onto treatment at a very
young age:
It brings hope that time will come and you stop taking
even the one pill and [that one day you will] completely
stop taking drugs (Uganda, CT arm)
One participant who was moved back onto the CT arm
having had a spike in his/her viral load described his/
her response to the trial results:
Because I have ever been there (on SCT). I know how it
feels, all the happiness in it. So even though I was a little
sad I still have hope that I will go back soon (to SCT).
(FGD, Uganda)
Response to the trial findings
The FGD participants in Uganda were delighted by the
trial results. Many described anticipating the outcome
that SCT would be ‘non-inferior’ given their own positive
experiences of the intervention, but the results further
endorsed their conﬁdence in the beneﬁts of SCT. This
suggests too that there may have been greater anxiety
about SCT than had been expressed during the trial:
When I heard the results, it gave me more courage to
adhere to the drugs and I saw that already we had
reached somewhere. We are on track. And it gave me
strength and I got to know that that if it was possible
then other things are coming.
We were so happy because when you get a break and
something went wrong and you felt bad. You would get
worried and wonder if it was because of missing. But
when we heard it had worked we all became happy.
Those on the CT arm were keen to begin on SCT as
soon as possible. There was, however, an understanding
of the need to stay in the same arms for the duration of
the trial follow-up. No one in the qualitative study on
the CT arm described informally practising ‘their own
SCT’ within the period of the trial. However, some FGD
participants discussed being sorely tempted to switch
themselves onto SCT after hearing the results. As such,
they were very keen that it should be rolled out soon to
those satisfying the relevant clinical criteria.
For me I would say that it is not good to make a child get
used to taking milk which you will not be able to provide.
You rather not and make them get used to black tea.
Despite their own positive overall experiences of SCT,
many participants, from both arms, were concerned that
the idea of SCT could disrupt the clarity of the adher-
ence messages young people are given. Many of these
young people would generally describe their own adher-
ence as relatively good. Hence, they were anxious that
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although SCT had helped them, those who were having
greater struggles with adherence would not be able to
manage the structure and discipline required to adapt
to the treatment interruption.
Many were thus concerned about what other positive
young people might do once the trial results are made
public and felt that other young people should not be
told about SCT for fear of how they might apply this to
their own treatment taking without supervision or moni-
toring: ‘They will misinterpret the study’; ‘They will say
that let us also do what they are doing, yet they don’t
have all the facts’.
DISCUSSION
Findings from this qualitative study indicate that those
on the SCT arm, after taking some time to adapt,
expressed a preference for taking the weekends off treat-
ment, which suggests that SCT was acceptable to them.
Although preferred to CT by those in the trial, SCT may
not be a viable option for everyone, because even ‘exem-
plary adherers’ like the young people in our study
encountered initial challenges in adapting to the new
routine.
The study highlighted patterns of non-disclosure of
adherence behaviours common among young people
living with HIV.5 18 19 However, our data have further
illustrated how young people use clinical indicators to
gauge whether to share information about ‘slippages’,
and to justify non-disclosure of adherence issues. They
interpret an undetectable viral load as a demonstration
that recent missed doses are not signiﬁcant. The extent
and impact of medication side effects were also consist-
ently under-reported to clinicians, and possibly within
the trial. Some participants had come to perceive these
side effects as inevitable and not worthy of mentioning
to clinic staff. Further research with young people on
EFV-based medication is urgently needed to understand
how side effects might affect their adherence and their
perceptions of themselves, health and HIV.20 21
A key limitation of our study is the narrow population
on which these ﬁndings are based (relying on those
agreeing to participate in the clinical trial and then also
in the qualitative substudy). Also, being in the trial may
have been conducive to better adherence, due to the
increased support and monitoring in the study, particu-
larly in contexts with little or no routine access to this
level of care. So far we have not explored the acceptabil-
ity of SCT among those who refused to take part in the
trial or were not eligible. It will be vital to include these
young people in the future to address acceptability of
SCT more broadly and robustly.
Including a qualitative study in the trial has enriched
our understanding of the impact and inﬂuence of SCT
on young people’s experiences of adherence. This is
likely to contribute to the wider success of the interven-
tion, by informing how SCT might be rolled out outside
of trial conditions. The intervention relies on young
people to change the ways in which they take their treat-
ment and they adhere to the structured 2 days interrup-
tion. Understanding their perspectives and experiences
is thus crucial for the intervention to be effective
beyond the trial. Despite an increasing recognition of
the pertinence of qualitative research to understand
pressing public health challenges, there is an ongoing
reticence among many leading clinical journals to
publish this research alongside trial ﬁndings.
SCT thus presents a unique opportunity to change the
conversation about ART with young people. By speciﬁc-
ally acknowledging adherence challenges in childhood
and adolescence, if framed thoughtfully, healthcare staff
can use SCT to show a greater contextual understanding
about the reasons why and ways in which treatment can
get disrupted. SCT could be used as a ‘reward’ for those
who can manage to adhere well, sustaining them on the
days ‘on’ ARTand/or an incentive for others to put more
effort into taking treatment and lowering viral load.
Yet, thoughtful planning and framing of SCT to young
people is necessary for these potential beneﬁts to be rea-
lised. As a patient-managed strategy, participants felt that
SCT could pose signiﬁcant risk to other young people
who may independently take treatment breaks under
inappropriate conditions and without assessment and
monitoring. This provides further evidence of the need
for careful dissemination and communication post-trial.
The initial challenges described by so many partici-
pants need to be taken into serious consideration when
planning any further intervention. The adaptation
period, although different for different participants, was
generally only short lived but it should not be underesti-
mated. Our ﬁndings emphasise the importance of
incorporating a package of interventions to accompany
any roll-out of SCT to support young people in adapting
to their new routine. We would anticipate that speciﬁc
support should be provided for 12–16 weeks to accom-
pany the adaptation period for those switching to SCT
and that this should be preceded by a 2–4-week prepar-
ation period of education and counselling to alleviate
concerns and ensure effective understanding about the
weekend break. Participants also suggested that such an
intervention during this period may be further strength-
ened by incorporating peer support from those already
on SCT. Any intervention should be subject to ongoing
evaluation. Provided early adjustments are carefully
managed through a tailored brief support programme,
the study has shown that SCT could be successfully trans-
formed into a welcome treatment option for young
people living with HIV.
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